Monthly Archives: April 2015
Notice of NPO New Membership and Membership Renewal for 2015 (Fee/Bank Account)
Cure Sarcoma welcomes sarcoma patients, their families and any others who can support our activities.
Please pay the new and renewal annual membership fee to the following bank account:
Annual fee: individual member: 3,000 yen; corporate member: 30,000 yen
Bank Account Mizuho Bank Omori Branch Account No.:1510100 Account Name：特定非営利活動法人キュアサルコーマ (NPO Cure Sarcoma)
Once we confirm the completion of membership registration and fee transfer, we will send an e-mail to you.
Difference among Cure Sarcoma Center, NPO Cure Sarcoma, and S-net
There seems to be some confusion about the difference among three organizations; General Incorporated Association Cure Sarcoma Center, NPO Cure Sarcoma, and S-net. We will explain briefly as below:
General Incorporated Association Cure Sarcoma Center This is an organization to support clinical treatment of adult soft tissue sarcomas mainly by Cure Sarcoma Board hospitals.
NPO Cure Sarcoma This is our group with sarcoma patients and their supporting members.
S-net This is a closed SNS communication site for sarcoma patients and their supporting members.
1st Ordinary general meeting is to be held
NPO Cure Sarcoma’s first ordinary general meeting is to be held as follows:
Time: 3-5pm March 21, 2014
Place: Tokyo Shigoto Center
Subject: Part 1- General Meeting; Part 2- Information Sharing Meeting
An over-dinner gathering is planned from 5:30 p.m. after the ordinary general meeting.
10th Sarcoma Seminar is to be held
10th Sarcoma Seminar is to be held: NPO Cure Sarcoma is going to co-sponsor 10th Sarcoma Seminar with General Incorporated Association Cure Sarcoma Center as follows:
Time: 10 a.m. – 6 p.m., February 26, 2015
Place: Luke Hall, Mochida Pharmaceutical Co. Ltd.
Dr. Nomori: Cryosurgery on malignant lung tumors
Dr. Koike: RFA on liver tumors
Dr. Takahashi: Status report on leiomyosarcoma treatment
Dr. Ohno, Dr. Hatae, Dr. Yajima, Dr. Teraoka: Status reports on sarcoma surgery treatments
Status report on treatment using Vascular Endothelial Growth Factor (VEGF) inhibitor Pazopanib (Votrient)
Dr. Koyama, Dr. Oyama:
Status report on international clinical study of newly developed sarcoma remedy
An over-dinner gathering is planned from 6 p.m. after the seminar.
Report from attending Japan-US International Sarcoma Workshop
On December 4 and 5, five members including myself from NPO Cure Sarcoma (an organization of adult soft tissue sarcoma patients and families) attended the workshop “The Japan-United States International Workshop on the Sarcoma Research and Therapy” in Honolulu, Hawaii. This workshop acted as a kickoff meeting of the Japanese Sarcoma Association. We were looking forward to attend the conference and hear the expected progress.
It was very refreshing to hear the presentations of familiar Japanese doctors in English. We learned the two new treatments (combination use of pazopanib and denosumab to the bone metastasis of soft tissue sarcomas, and cryosurgery) for the first time at this conference.
The presentation from Dr. Brohl about genome analysis on Ewing sarcoma was very difficult. We found some differences between Japan and US during the conference. For example, there are more liposarcoma patients than leiomyosarcoma patients in the US. Ion beam radiotherapy is in more advanced use in Japan.
Dr. Takahashi’s group had more patient cases in their presentations because the sarcoma patients came mostly to this group for help. We felt that the Japanese treatment results in surgery, local treatment, and the use of pazopanib were equal to those of US results. We got an impression that the US treatment methods did not differ a lot, but there were more clinical trials conducted in the US in chemotherapy area.
We eagerly hope that a deep international discussion on sarcoma study and treatment will be done and the best standard treatment method will soon be established for sarcoma patients. We NPO Cure Sarcoma will try our best to support the development of sarcoma treatments.
December 21, 2014 NPO Cure Sarcoma Hiroyuki Onishi, Chairman of the Board of Trustees